One of the hardest things to do as a medtech founder is stay narrow. Every conversation with a customer surfaces some new idea about what the product could also do, and every conversation with an investor surfaces some new idea about a bigger market you could also address. The pressure to widen is constant.
VynMed's product is narrow on purpose. Here's what it doesn't do, so you know where the edges are.
VynMed is not a diagnostic test. We don't make the strip. We don't change the chemistry. We don't claim clinical performance beyond what the strip manufacturer already claims. The diagnostic value of a VynScan read is inherited directly from the underlying FDA-cleared strip. Our job is to read and report that existing result consistently and quickly.
VynMed is not a lab. We're not processing samples, running reagents, or producing laboratory-derived results. We're reading a result that the strip has already generated. A lab has a different regulatory posture, a different workflow, and a different business model. Ours is simpler on purpose.
VynMed is not trying to replace any existing strip manufacturer. We're downstream of them. The more strip vendors there are, the better for us. Every strip manufacturer who produces a quality cleared product makes VynScan more valuable to its customers. We hope to partner with several strip vendors over time, not compete with them.
VynMed is not an AI diagnostic company. There's computer vision in the reader, yes, but it's narrow purpose-built software that measures line intensity against known reference positions on a known strip geometry. It's not a black-box neural network making clinical interpretations on its own. Every reading can be traced back to specific pixel measurements against specific thresholds. That traceability is important for FDA, for audits, and for us.
VynMed is not targeting hospitals right now. Our go-to-market is skilled nursing, assisted living, and similar long-term care environments. Hospitals already have fast on-site labs and their staffing and workflow are fundamentally different. Hospitals are a potential future market, not a current one. We're not going to get distracted by pilots in a setting where the customer need is weaker.
VynMed is not trying to become a consumer device. VynScan is not designed for home use, it is not intended for untrained users, and it is not going to be sold direct to residents. Our customer is the facility and the user is a trained nurse or CNA. The product is designed around that use context and nothing else.
VynMed is not a platform play. Not yet. The temptation to pitch a "workflow platform for SNFs" is real and it's one I've had to talk myself out of multiple times. A platform is what VynMed might become in five years. Right now, it's a reader that does one job in a specific workflow, and that narrowness is the reason it can ship.
Clarity about what you aren't is usually more valuable than claims about what you are. That's true in product design, it's true in positioning, and it's especially true in early-stage fundraising conversations where every founder is tempted to stretch to match what the investor in the room wants to hear.